Back to top

Eledon Pharmaceuticals initiated with a Buy at Rodman & Renshaw

Rodman & Renshaw analyst Seema Sheoran initiated coverage of Eledon Pharmaceuticals (ELDN) with a Buy rating and $12 price target implying 200% ups...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Eledon Pharmaceuticals, Inc. (ELDN)